Belhaven Biopharma Inc. has filed a notice of an exempt offering of securities to raise $32,289,627.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Belhaven Biopharma Inc. is raising up to $32,289,627.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Belhaven Biopharma Inc.
At Belhaven Biopharma, our focus extends beyond immediate solutions to pioneering a future where emergency medications are more affordable, effective, and user-friendly. Our mission is to ensure that life saving medications are universally accessible and simpler to use through the development of dry powder nasal formulations. Founded in 2021 in Raleigh, North Carolina, Belhaven Biopharma was created with the mission to bring life changing anaphylaxis treatment to patients worldwide. With support from the North Carolina Biotechnology Center and a team of visionary leaders, we are dedicated to enhancing emergency medical care.
To learn more about Belhaven Biopharma Inc., visit https://belhavenbio.com/
Belhaven Biopharma Inc. Linkedin Page: https://www.linkedin.com/company/belhaven-biopharma/
Contact:
Scott Lyman, President and Chief Executive Officer
919-656-8658
https://www.linkedin.com/in/scott–lyman/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.